Clinical trials: Controlled Hypertension
Glaucoma, Ocular Hypertension
AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure
This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular…
- Trial name
- NCT01474135
- Testing
- 0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost
- Where
- 9 sites in United States
- Volunteers
- 93 people
- Sponsor
- Aerie Pharmaceuticals
Hypertension
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
The purpose of this study is to determine the effectiveness of candesartan cilexetil in preventing hypertension in people with high normal blood pressure.
- Trial name
- NCT00227318
- Testing
- ATACAND
- Where
- 42 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients…
- Conditions
- Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
- Trial name
- NAVIGATE (NCT04365868)
- Testing
- belapectin
- Where
- 156 sites in United States, Argentina and 13 more
- Volunteers
- 357 people
- Sponsor
- Galectin Therapeutics Inc.
Hypertension, Essential, Primary Hypercholesterolemia
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
- Trial name
- NCT06448962
- Testing
- AD-2021, AD-2022
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Addpharma Inc.
Hypertension (HTN)
QLS1410 in Participants With Uncontrolled Hypertension
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN).
- Trial name
- NCT07489612
- Testing
- Dose 1 of QLS1410, Dose 2 of QLS1410, Dose 3 of QLS1410
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Chronic Kidney Diseases, Hypertension
Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
This is a Phase 2 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy, safety, and pharmacokinetics of KBP-5074 in patients with moderate-to-severe chronic kidney disease and uncontrolled…
- Trial name
- BLOCKCKD (NCT03574363)
- Testing
- KBP-5074 0.25 mg tablet, KBP-5074 0.5 mg tablet
- Where
- 2 sites in United States
- Volunteers
- 162 people
- Sponsor
- KBP Biosciences
Hypertension
MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)
This study is being conducted to evaluate the efficacy of MK-0954A in essential hypertension participants who are not adequately controlled with losartan.
- Trial name
- NCT01307046
- Testing
- MK-0954A, Losartan
- Volunteers
- 336 people
- Sponsor
- Organon and Co
Mild Hypertension
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.
- Trial name
- NCT06905327
- Testing
- QCZ484
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Evaluate the efficacy (blood pressure lowering effect) and safety of aliskiren alone and in combination with amlodipine in patients with essential hypertension.
- Trial name
- NCT00739973
- Testing
- Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 2,694 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
- Trial name
- REPLACE (NCT02891850)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Where
- 81 sites in United States, Austria and 19 more
- Volunteers
- 225 people
- Sponsor
- Bayer
Uncontrolled Hypertension
REGN5381 in Adult Participants With Uncontrolled Hypertension
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on uncontrolled hypertension (high blood pressure despite being on one or more antihypertensive drugs).
- Trial name
- NATRIX-SBP (NCT06833190)
- Testing
- REGN5381
- Where
- 3 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Regeneron Pharmaceuticals
Normal Tension Glaucoma (NTG)
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension…
- Trial name
- NCT04857827
- Testing
- QLS-101, Timolol maleate PF 0.5% ophthalmic solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Qlaris Bio, Inc.
Hypertension, High Blood Pressure
A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension
To evaluate the safety and effectiveness of the ROX Coupler used to create an arteriovenous anastomosis in the iliac region (between the iliac artery and vein) in subjects with hypertension.
- Trial name
- CONTROL HTN-2 (NCT02895386)
- Testing
- ROX Coupler
- Where
- 13 sites in United States
- Volunteers
- 30 people
- Sponsor
- ROX Medical, Inc.
Obesity, Hypertension
A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to compare the efficacy and safety of daily topiramate (96mg or 192mg) versus placebo in obese patients with mild to moderate high blood pressure.
- Trial name
- NCT00236665
- Testing
- topiramate
- Volunteers
- 531 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
This study is a phase 2 study in patients with essential hypertension.
- Trial name
- NCT01193101
- Testing
- LCZ696
- Where
- 34 sites in China, Japan and 3 more
- Volunteers
- 389 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
The purpose of the study is to assess the safety, tolerability, and IOP effects of RO5093151 following 7 days of topical ocular treatment in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02622334
- Testing
- Latanoprost, RO5093151
- Where
- 7 sites in United States, Singapore
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Pulmonary Arterial Hypertension
Tezosentan in Patients With Pulmonary Arterial Hypertension
Multicenter, double-blind, randomized, placebo-controlled, cross-over study to demonstrate that a single infusion of tezosentan has minimal effect on blood pressure in patients with pulmonary arterial hypertension, treated with…
- Trial name
- NCT01094067
- Testing
- ACT-050089
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Ocular Hypertension, Open Angle Glaucoma
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
This study is designed to see how safe and effective a new eye drop, called Reformulated PG324, is for lowering eye pressure in people with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT07082816
- Testing
- Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution
- Where
- 30 sites in United States
- Volunteers
- 489 people
- Sponsor
- Alcon Research
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Pulmonary Artery Hypertension
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.
- Trial name
- NCT04456998
- Testing
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Where
- 63 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.